{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:25:41Z","timestamp":1776356741241,"version":"3.51.2"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS112779-01A1"],"award-info":[{"award-number":["R21NS112779-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.nbd.2021.105410","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T12:20:44Z","timestamp":1622550044000},"page":"105410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src\/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy"],"prefix":"10.1016","volume":"156","author":[{"given":"Shaunik","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Gregory-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Hinojo-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thimmasettappa","family":"Thippeswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2021.105410_bb0005","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1074\/jbc.M506172200","article-title":"NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox","volume":"281","author":"Anrather","year":"2006","journal-title":"Biol. Chem."},{"key":"10.1016\/j.nbd.2021.105410_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/DDDT.S75495","article-title":"Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models","volume":"19","author":"Ba","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.nbd.2021.105410_bb0015","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","article-title":"Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors","volume":"16","author":"Baselga","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.nbd.2021.105410_bb0020","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1111\/j.1460-9568.2012.08234.x","article-title":"N (w) -propyl-L-arginine (L-NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses","volume":"36","author":"Beamer","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2021.105410_bb0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40261-018-0676-7","article-title":"Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of chronic Myeloid Leukemia","volume":"38","author":"Bettiol","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.nbd.2021.105410_bb0030","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.173.9.5730","article-title":"Protein kinase C delta is required for p47phox phosphorylation and translocation in activated human monocytes","volume":"73","author":"Bey","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.nbd.2021.105410_bb0035","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1460-9568.1995.tb01131.x","article-title":"Physiological and morphological heterogeneity of dentate gyrus-hilus interneurons in the gerbil hippocampus in vivo","volume":"7","author":"Buckmaster","year":"1995","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2021.105410_bb0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s12035-016-9695-7","article-title":"Combining normobaric oxygen with ethanol or hypothermia prevents brain damage from thromboembolic stroke via PKC-Akt-NOX modulation","volume":"54","author":"Cai","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2021.105410_bb0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nbd.2008.02.005","article-title":"Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure","volume":"30","author":"Cosgrave","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","article-title":"Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy","volume":"52","author":"Curatolo","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.nbd.2021.105410_bb0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","article-title":"The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts","volume":"7","author":"deVries","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.nbd.2021.105410_bb0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5698\/1535-7597-16.1.24","article-title":"Imaging brain inflammation: if we can see it, maybe we can treat it","volume":"16","author":"French","year":"2016","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.nbd.2021.105410_bb0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10637-012-9809-7","article-title":"First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours","volume":"31","author":"Fujisaka","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.nbd.2021.105410_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-020-00787-5","article-title":"Inhibitors of Src family kinases, inducible nitric oxide synthase, and NADPH oxidase as potential CNS drug targets for neurological diseases","volume":"35","author":"Gage","year":"2021","journal-title":"CNS Drugs."},{"key":"10.1016\/j.nbd.2021.105410_bb0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2016.04.008","article-title":"Protein kinase C\u03b4 upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease","volume":"93","author":"Gordon","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","article-title":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","volume":"3","author":"Green","year":"2009","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.nbd.2021.105410_bb0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","article-title":"Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer","volume":"11","author":"Gucalp","year":"2011","journal-title":"Clin. Breast Cancer."},{"key":"10.1016\/j.nbd.2021.105410_bb0090","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methypiperazin 1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highlyselective, orally available, dual-specific c-Src\/Abl kinase inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.nbd.2021.105410_bb4000","doi-asserted-by":"crossref","first-page":"30712","DOI":"10.18632\/oncotarget.8750","article-title":"SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma","volume":"7","author":"Heusschen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.nbd.2021.105410_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbagen.2007.11.010","article-title":"Glycated human serum albumin enhances macrophage inflammatory protein-1beta mRNA expression through protein kinase C-delta and NADPH oxidase in macrophage-like differentiated U937 cells","volume":"1780","author":"Higai","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2021.105410_bb0100","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1074\/jbc.M113.508663","article-title":"The inducible nitric oxide synthase (iNOS)\/Src axis mediates toll-like receptor 3 tyrosine 759 phosphorylation and enhances its signal transduction, leading to interferon-\u03b2 synthesis in macrophages","volume":"289","author":"Hsieh","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2021.105410_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1593\/tlo.09280","article-title":"Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib","volume":"3","author":"Kast","year":"2010","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.nbd.2021.105410_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fncel.2017.00267","article-title":"p47Phox\/CDK5\/DRP1-mediated mitochondrial fission evokes PV cell degeneration in the rat dentate gyrus following status epilepticus","volume":"11","author":"Kim","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2021.105410_bb0115","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1089\/ars.2016.6905","article-title":"Mito-Apocynin prevents mitochondrial dysfunction, microglial activation, oxidative damage, and progressive neurodegeneration in MitoPark transgenic mice","volume":"27","author":"Langley","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.nbd.2021.105410_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","article-title":"Dasatinib","volume":"201","author":"Lindauer","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.nbd.2021.105410_bb0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.27649","article-title":"Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo","volume":"132","author":"Liu","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.nbd.2021.105410_bb0130","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.3125","article-title":"Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor","volume":"23","author":"Lockton","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.nbd.2021.105410_bb0135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/0008-5472.CAN-13-0588","article-title":"Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2","volume":"74","author":"Lopez-Rivera","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.nbd.2021.105410_bb0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12868-020-00606-z","article-title":"Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice","volume":"22","author":"Luo","year":"2021","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.nbd.2021.105410_bb0145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbamcr.2010.09.004","article-title":"The iNOS\/Src\/FAK axis is critical in toll-like receptor-mediated cell motility in macrophages","volume":"1813","author":"Maa","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2021.105410_bb0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1535-7163.MCT-15-0093","article-title":"ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B-driven brainstem glioma model","volume":"15","author":"Mittapalli","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.nbd.2021.105410_bb0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/alzrt238","article-title":"Fyn kinase inhibition as a novel therapy for Alzheimer's disease","volume":"6","author":"Nygaard","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2021.105410_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2021.105410_bb0165","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1523\/JNEUROSCI.0302-15.2015","article-title":"Fyn kinase regulates microglial Neuroinflammatory responses in cell culture and animal models of Parkinson's disease","volume":"35","author":"Panicker","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2021.105410_bb0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.nbd.2015.07.005","article-title":"Reactive oxygen species mediate cognitive deficits in experimental temporal lobe epilepsy","volume":"82","author":"Pearson","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0180","doi-asserted-by":"crossref","first-page":"104443","DOI":"10.1016\/j.nbd.2019.03.031","article-title":"Inducible nitric oxide synthase inhibitor, 1400W, mitigates DFP-induced long-term neurotoxicity in the rat model","volume":"133","author":"Putra","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/nyas.14314","article-title":"Diapocynin, an NADPH oxidase inhibitor, counteracts diisopropylfluorophosphate-induced long-term neurotoxicity in the rat model","volume":"1479","author":"Putra","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.nbd.2021.105410_bb0190","doi-asserted-by":"crossref","first-page":"592374","DOI":"10.3389\/fncel.2020.592374","article-title":"Fyn-tau ablation modifies PTZ-induced seizures and post-seizure hallmarks of early epileptogenesis","volume":"14","author":"Putra","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"7","key":"10.1016\/j.nbd.2021.105410_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131705","article-title":"Immediate epileptogenesis after kainate-induced status epilepticus in C57BL\/6J mice: evidence from long-term continuous video-EEG telemetry","volume":"10","author":"Puttachary","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2021.105410_bb0200","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2016.05.013","article-title":"1400W, a highly selective inducible nitric oxide synthase inhibitor is a potential disease modifier in the rat kainate model of temporal lobe epilepsy","volume":"93","author":"Puttachary","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2741\/e775","article-title":"Immediate epileptogenesis: impact on brain in C57BL\/6J mouse kainate model","volume":"8","author":"Puttachary","year":"2016","journal-title":"Front. Biosci. (Elite Ed)."},{"key":"10.1016\/j.nbd.2021.105410_bb2000","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation","volume":"32","author":"Racine","year":"1972","journal-title":"II. Motor seizure. Electroencephalogr Clin Neurophysiol."},{"key":"10.1016\/j.nbd.2021.105410_bb0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.nbd.2015.07.003","article-title":"GABAA currents are decreased by IL-1\u03b2 in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis","volume":"82","author":"Roseti","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0215","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"9","author":"Shah","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.nbd.2021.105410_bb0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nbd.2017.11.008","article-title":"Role of the Fyn-PKC\u03b4 signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy","volume":"110","author":"Sharma","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2021.105410_bb0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fneur.2018.00007","article-title":"Status epilepticus: behavioral and electroencephalography seizure correlates in kainate experimental models","volume":"9","author":"Sharma","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nbd.2021.105410_bb0230","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/cne.20850","article-title":"Kainic acid-induced recurrent mossy fiber innervation of dentate gyrus inhibitory interneurons: possible anatomical substrate of granule cell hyper-inhibition in chronically epileptic rats","volume":"494","author":"Sloviter","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2021.105410_bb0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropharm.2017.11.042","article-title":"Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model","volume":"130","author":"Smith","year":"2017","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.nbd.2021.105410_bb0240","series-title":"Interictal Spikes and Epileptogenesis","first-page":"199","volume":"6(6)","author":"Staley","year":"2006"},{"key":"10.1016\/j.nbd.2021.105410_bb0245","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neulet.2011.03.070","article-title":"Interictal spikes: harbingers or causes of epilepsy?","volume":"497","author":"Staley","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2021.105410_bb0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1471-4159.2008.05616.x","article-title":"Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction","volume":"107","author":"Sun","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2021.105410_bb0255","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1528-1157.2001.28900.x","article-title":"Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials","volume":"42","author":"Temkin","year":"2011","journal-title":"Epilepsia."},{"issue":"5","key":"10.1016\/j.nbd.2021.105410_bb3000","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096622","article-title":"Advantages of Repeated Low Dose against Single High Dose of Kainate in C57BL\/6J Mouse Model of Status Epilepticus: Behavioral and Electroencephalographic Studies","volume":"9","author":"Tse","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nbd.2021.105410_bb5000","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1074\/jbc.M109.055038","article-title":"Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells","volume":"285","author":"Tyryshkin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nbd.2021.105410_bb0260","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-13-1256","article-title":"SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis","volume":"74","author":"Tyryshkin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.nbd.2021.105410_bb0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-pharmtox-010814-124607","article-title":"Candidate drug targets for prevention or modification of epilepsy","volume":"55","author":"Varvel","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"38","key":"10.1016\/j.nbd.2021.105410_bb6000","doi-asserted-by":"crossref","first-page":"E5665","DOI":"10.1073\/pnas.1604263113","article-title":"Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus","volume":"113","author":"Varvel","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nbd.2021.105410_bb0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.expneurol.2011.09.033","article-title":"Epilepsy and brain inflammation","volume":"244","author":"Vezzani","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2021.105410_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-91439-8_1","article-title":"Imatinib mesylate","volume":"212","author":"Waller","year":"2018","journal-title":"Recent Results Cancer Res."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996121001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996121001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:27:41Z","timestamp":1760851661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996121001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":59,"alternative-id":["S0969996121001595"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2021.105410","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src\/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2021.105410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105410"}}